These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3443671)

  • 21. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population.
    Mbanefo C; Bababunmi EA; Mahgoub A; Sloan TP; Idle JR; Smith RL
    Xenobiotica; 1980 Nov; 10(11):811-8. PubMed ID: 7467396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of debrisoquine and metabolites in human urine by gas chromatography-mass spectrometry.
    Daumas L; Sabot JF; Vermeulen E; Clapot P; Allegre F; Pinatel H; Boucherat M; Francois B
    J Chromatogr; 1991 Sep; 570(1):89-97. PubMed ID: 1797839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphic debrisoquin metabolism in a Turkish population.
    Bozkurt A; Basci NE; Isimer A; Sayal A; Kayaalp SO
    Clin Pharmacol Ther; 1994 Apr; 55(4):399-401. PubMed ID: 8162666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
    Speirs CJ; Murray S; Davies DS; Biola Mabadeje AF; Boobis AR
    Br J Clin Pharmacol; 1990 Jan; 29(1):101-9. PubMed ID: 2153391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
    Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
    Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Debrisoquin oxidation polymorphism in a Spanish population.
    Benítez J; LLerena A; Cobaleda J
    Clin Pharmacol Ther; 1988 Jul; 44(1):74-7. PubMed ID: 3391005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of debrisoquine and 4-hydroxydebrisoquine in urine by high-performance liquid chromatography with fluorescence detection after solid-phase extraction.
    Bozkurt A; Basci NE; Isimer A; Kayaalp SO
    J Pharm Biomed Anal; 1993 Aug; 11(8):745-9. PubMed ID: 8257740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The metabolism of [14C]-debrisoquine in man.
    Idle JR; Mahgoub A; Angelo MM; Dring LG; Lancaster R; Smith RL
    Br J Clin Pharmacol; 1979 Mar; 7(3):257-66. PubMed ID: 371651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography.
    Pereira VA; Auler JO; Carmona MJ; Mateus FH; Lanchote VL; Breimer DD; Santos SR
    Braz J Med Biol Res; 2000 May; 33(5):509-14. PubMed ID: 10775881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
    Caporaso N; Pickle LW; Bale S; Ayesh R; Hetzel M; Idle J
    Genet Epidemiol; 1989; 6(4):517-24. PubMed ID: 2777072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin.
    Woosley RL; Roden DM; Dai GH; Wang T; Altenbern D; Oates J; Wilkinson GR
    Clin Pharmacol Ther; 1986 Mar; 39(3):282-7. PubMed ID: 3081292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.
    Atiba JO; Blaschke TF; Wilkinson GR
    Br J Clin Pharmacol; 1989 Aug; 28(2):161-5. PubMed ID: 2775621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxidation phenotyping with debrisoquine in Germany (East).
    Zschiesche M; Hanke W; Siegmund W; Franke G; Wilke A
    Pharmazie; 1990 Dec; 45(12):920-1. PubMed ID: 2100800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.
    Philip PA; James CA; Rogers HJ
    Br J Clin Pharmacol; 1987 Dec; 24(6):827-9. PubMed ID: 3440103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.
    Eichelbaum M; Bertilsson L; Küpfer A; Steiner E; Meese CO
    Br J Clin Pharmacol; 1988 Apr; 25(4):505-8. PubMed ID: 3382592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.